uniQure (NASDAQ:QURE) Raised to Hold at Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research firms also recently commented on QURE. Leerink Partners reissued an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research report on Monday, March 2nd. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Finally, TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.75.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $14.77 on Friday. The firm has a market cap of $923.57 million, a price-to-earnings ratio of -4.28 and a beta of 0.73. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The business has a fifty day simple moving average of $19.91 and a 200 day simple moving average of $29.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, sell-side analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 14,581 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares in the company, valued at $5,985,561.48. This represents a 2.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Gut sold 25,613 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 81,399 shares of company stock worth $1,527,645. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new position in shares of uniQure in the third quarter valued at $28,000. Torren Management LLC bought a new position in shares of uniQure during the 4th quarter worth about $28,000. Jones Financial Companies Lllp boosted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. IFP Advisors Inc bought a new stake in uniQure in the fourth quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC acquired a new stake in uniQure during the fourth quarter valued at approximately $48,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.